Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.
Adv TherJun 11, 2026 (epub)
Mazyar Shadman, Talha Munir, Sheng Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This comparative study evaluated the efficacy of zanubrutinib versus ibrutinib and acalabrutinib in treatment-naive chronic lymphocytic leukemia (CLL) over a 6-year follow-up. Results indicated that zanubrutinib significantly prolonged progression-free survival (PFS-INV) with a hazard ratio of 0.65 and showed a trend toward improved overall survival (OS) compared to ibrutinib. The study utilized indirect comparisons from phase 3 trials.
Key findings
- Zanubrutinib significantly prolonged PFS-INV compared to ibrutinib (HR, 0.65; P = 0.0330).
- At 72 months, PFS-INV rates were 15.3% higher with zanubrutinib versus ibrutinib.
- Zanubrutinib trended toward improved OS compared to acalabrutinib (HR, 0.66; P = 0.0836).
- At 72 months, OS rates were 8.8% higher with zanubrutinib versus acalabrutinib.
Why it matters
Understanding the long-term efficacy of different Bruton tyrosine kinase inhibitors is crucial for optimizing treatment strategies in chronic lymphocytic leukemia, potentially leading to better patient outcomes.